Literature DB >> 25890047

Mixed large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder: a case report and brief review of the literature.

Wei Liu1, Lei Wang2, Xiao-dong He3, Cheng Feng4, Xiao-yan Chang5, Zhao-hui Lu6.   

Abstract

Large-cell neuroendocrine carcinoma (LCNEC) of the gallbladder is extremely rare. We present a 63-year-old Chinese female who was admitted with right upper quadrant pain and a quasi-circular tumor measuring 2.0 cm on the body of the gallbladder, as indicated by computed tomography. LCNEC combined with adenocarcinoma was immunohistochemically confirmed after open radical cholecystectomy. Postoperative recovery of this patient was uneventful, and no evidence of recurrence or metastasis was observed after 12 months of follow-up. LCNEC of the gallbladder is thought to be extremely rare and is usually found in combination with other histological carcinoma types, such as adenocarcinoma, as determined histologically. The prognosis is poor overall, but early detection with complete resection may result in a relatively good prognosis.

Entities:  

Mesh:

Year:  2015        PMID: 25890047      PMCID: PMC4365805          DOI: 10.1186/s12957-015-0533-6

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Neuroendocrine neoplasms (NENs) account for 1.25% of all malignancies, with the majority (66%) occurring in the gastrointestinal tract, followed by the bronchopulmonary system (31%). Other less frequent locations include the ovaries, testes, pancreas, and hepatobiliary system. Gallbladder NENs are particularly rare, and 278 cases were registered in the Surveillance, Epidemiology and End Results (SEER) from 1973 to 2005, only representing 0.5% of all NENs and approximately 2% of all gallbladder cancers [1,2]. Among all NENs originating in the gallbladder, large-cell neuroendocrine carcinoma (LCNEC) is exceedingly rare, and the first case worldwide was reported in 2000 [3]. To date, although several case reports of gallbladder LCNEC have been published [3-16] (Table 1), its biological behavior, the appropriate treatment modalities, and the overall patient prognosis remain largely unclear. Herein, we report a rare case of gallbladder LCNEC and present a brief literature review to contribute to the increased understanding of the clinical features of this disease.
Table 1

Clinicopathological features of 17 cases of large-cell neuroendocrine carcinoma of the gallbladder

Number Author [ref.] Gender/ age Presentation Tumor location Tumor size (cm) Liver invasion Metastasis Other component Treatments Prognosis, follow-up (month)
1Papotti et al. [3]M/50UnclearUnclear<1--ACChoDFS, 12
2Papotti et al. [3]M/65UnclearFundus2.5-Liver-ChoDied, 14
3Jun et al. [4]M/55AP, jaundiceUnclearUnclearUnclearLymph node-Needle biopsy, CheDied, 1
4Jun et al. [4]F/67APUnclearHuge+Lymph node-Needle biopsy, CheDied, 10
5Noske and Pahl [5]F/81AP, jaundiceNeck5+BoneAdenosquamousPalliative surgeryUnknown
6Oshiro et al. [6]F/55Back pain, feverBody4.9--AC, SCNECRadical ChoDFS, 20
7Shimono et al. [7]F/64APUnclear11.5+--Che, Rad, extended hepatectomyDFS, 36
8Iype et al. [8]M/85Anorexia, weight lossFundus1.5-UnclearACCho, CheDied, 21
9Lin et al. [9]F/65Cushing’s syndromeBodyUnclear---(ACTH-producing)Radical Cho, CheDied, 2
10Sato et al. [10]F/68NegativeFundus3+Lymph nodeACCho, extended hepatectomyDFS, 12
11Paniz et al. [11]F/48APFundus3.5+UnclearACCho, extended hepatectomyUnknown
12Al-Brahim and Albannai [12]M/45AP, jaundiceFundus5.7+UnclearACCho, CheUnknown
13Okuyam et al. [13]M/64Abdominal fullnessFundus2.5+Lymph node-Biopsy, CheDied, 22
14Nakagawa et al. [14]M/56ExophthalmosUnclear9+MultipleACChe, RadDied, 36
15Meguro et al. [15]F/54NegativeUnclearUnclear--ACCho, extrahepatic bile duct resectionDFS, 24
16Russo et al. [16]M/59APBody4+Lymph nodeMucinous carcinomaRadical ChoUnknown
17Current study, 2014F/63AP, feverBody2.0--ACRadical ChoDFS, 12

AP, abdominal pain; AC, adenocarcinoma; ACTH, adrenocorticotropic hormone; Che, chemotherapy; Cho, cholecystectomy; DFS, disease-free survival; F, female; M, male; Rad, radiotherapy; SCNEC, small-cell neuroendocrine carcinoma.

Clinicopathological features of 17 cases of large-cell neuroendocrine carcinoma of the gallbladder AP, abdominal pain; AC, adenocarcinoma; ACTH, adrenocorticotropic hormone; Che, chemotherapy; Cho, cholecystectomy; DFS, disease-free survival; F, female; M, male; Rad, radiotherapy; SCNEC, small-cell neuroendocrine carcinoma.

Case presentation

A 63-year-old woman came to our emergency room on 14 July 2013, with a history of intermittent right upper quadrant pain that began 3 months prior. Ultrasound indicated no other anomalies, except for a focal thickening of the gallbladder wall. Computed tomography (CT) showed a suspected mass measuring 0.6 × 0.3 cm on the gallbladder plica (Figure 1a). Because she had a past medical history of cholecystitis, we could not clearly determine whether the mass was a tumor or only thickened mucosa; thus, watchful follow-up was recommended to the patient. On the 29 of October 2013, the patient returned to our clinic, and CT scan revealed a 2.0 × 1.8 cm quasi-circular tumor located on the body of the gallbladder in the same location as the mass detected 3.5 months earlier, with significant enhancement in the portal venous phase (Figure 1b). The results of laboratory tests, including tests for tumor markers and hormonal profiles, were all within normal limits.
Figure 1

A fast-growing tumor located on the body of the gallbladder. (a) Computed tomography showed a suspected mass, measuring 0.6 cm, on the gallbladder plica 3.5 months prior. (b) At admission 3.5 months later, CT showed a 2.0 × 1.8 cm quasi-circular mass located on the body of gallbladder, with significant enhancement in the portal venous phase.

A fast-growing tumor located on the body of the gallbladder. (a) Computed tomography showed a suspected mass, measuring 0.6 cm, on the gallbladder plica 3.5 months prior. (b) At admission 3.5 months later, CT showed a 2.0 × 1.8 cm quasi-circular mass located on the body of gallbladder, with significant enhancement in the portal venous phase. Laparoscopic cholecystectomy was performed, and an intraoperative frozen pathological section indicated that the lesion was malignant. Immediately thereafter, open radical cholecystectomy with resection of a wedge of the liver and the hepatoduodenal lymph nodes was performed. The gross specimen showed a cauliflower-shaped mass, and microscopically, the tumor consisted of the following two components: moderately differentiated adenocarcinoma and poorly differentiated large-cell neuroendocrine carcinoma (Figure 2a,b). Immunohistochemically, the neuroendocrine cells exhibited the strong expression of the neuroendocrine markers chromogranin A (Figure 2c) and synaptophysin (Figure 2d). In addition, these neuroendocrine cells showed a Ki67 index of over 80%. There was no evidence of serous or liver invasion or lymph node or distant metastasis. Thus, this lesion was assigned a final classification of pT2N0M0 stage II, according to the Union Internationale Contre le Cancer guidelines. The postoperative course of this patient was uneventful, and the carcinoma did not recur during a 12-month follow-up period.
Figure 2

Pathologically demonstrated mixed large-cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. (a) A low-power view (H&E, 100×) demonstrating the combination of a majority of poorly differentiated large cell neuroendocrine carcinoma (LCNEC) cells and a minority of moderately differentiated adenocarcinoma cells (right lower quadrant). (b) A high-power view (H&E, 400×) demonstrating that the neuroendocrine carcinoma cells were large in size, polygonal, and contained high numbers of mitotic figures. (c) Immunohistochemical staining showing that the LCNEC cells were positive for chromogranin A. (d) Immunohistochemical staining showing that the LCNEC cells were positive for synaptophysin.

Pathologically demonstrated mixed large-cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. (a) A low-power view (H&E, 100×) demonstrating the combination of a majority of poorly differentiated large cell neuroendocrine carcinoma (LCNEC) cells and a minority of moderately differentiated adenocarcinoma cells (right lower quadrant). (b) A high-power view (H&E, 400×) demonstrating that the neuroendocrine carcinoma cells were large in size, polygonal, and contained high numbers of mitotic figures. (c) Immunohistochemical staining showing that the LCNEC cells were positive for chromogranin A. (d) Immunohistochemical staining showing that the LCNEC cells were positive for synaptophysin. The present case report is in compliance with the Helsinki Declaration and has been approved by ethics committee of Peking Union Medical College Hospital.

Discussion

According to the latest World Health Organization (WHO) classification published in 2010 [17], NENs are classified into the following four general categories that are mainly based on mitotic count and the Ki67 proliferation index: (1) well differentiated neuroendocrine tumor (NET) or grade 1 tumor, with a mitotic count of <2/10 per high-power fields (HPF) and a Ki67 of ≤2%, such as a typical carcinoids; (2) intermediate differentiated NET or grade 2 tumor, with a mitotic count of between 2 and 20/10 HPF and a Ki67 of 3% to 20%, such as an atypical carcinoids; (3) poorly differentiated neuroendocrine carcinoma (NEC) or grade 3 tumor, with a mitotic count of >20/10 HPF and a Ki67 of >20%, which includes small-cell and large-cell NECs; and (4) mixed adenoneuroendocrine carcinoma (MANEC), histologically exhibiting concomitant adenocarcinoma (or other components) and NEC concomitantly. Primary gallbladder small-cell NEC (GB-SCNEC) is particularly rare, with only 74 cases described until 2011 [18]. Large-cell neuroendocrine carcinoma of the gallbladder (GB-LCNEC) is exceedingly rare and was first reported by Papotti in 2000 [3]. The histological features of LCNEC are as follows: (1) positivity for neuroendocrine markers, among which chromogranin A and synaptophysin are the most commonly identified; (2) a mitotic count exceeding 20/10 HPFs or a Ki67 index of over 20%; and (3) a specific NET pattern of an organoid structure, rosette formation, palisading, and trabecular arrangement, as well as prominent nuclei that are over three times the diameter of a lymphocyte. Although more than ten cases of GB-LCNEC have been reported in the English literature to date (Table 1), there is a paucity of data on this tumor type. We reviewed a series of 17 GB-LCNECs, including 16 previously reported cases and our present case. This series of GB-LCNECs included reports of 6 (35%) pure LCNECs and 11 (65%) LCNECs combined with other histological components, including 9 concomitant with adeno-, one with adenosquamous-, and one with mucinous carcinoma. Patients with mixed histological components were classified as having MANEC according to the WHO 2010 classification [17]. Only one tumor was found to be a functional ACTH-producing tumor in this series. Enterochromaffin cells, the precursor cells of NENs, are distributed throughout the gastrointestinal tract, bronchus, endocrine glands, and skin. These are also common sites of NEN. The gallbladder mucosa in the fundus and body is devoid of neuroendocrine cells, which may appear after intestinal metaplasia due to chronic inflammation. This fact explains why NENs rarely occur in the gallbladder. Virtually all published reports on gallbladder NENs describe coexisting gallstones and chronic cholecystitis [19]. Our patient presented non-specific vague abdominal pain in the right upper quadrant, which is a typical symptom of cholelithasis and should be considered a pathogenic basis of NEC. Similar to most previously reported cases of NEC, the clinical symptoms and radiological findings of our patient were nonspecific. According to the descriptions of the series of 17 GB-LCNECs, abdominal pain (8/17, 47%) was the most common symptom. Other symptoms, including fever, jaundice, and weight loss, were also nonspecific. SCNEC and LCNEC were confirmed to be genetically similar and distinct from well-differentiated NETs [20]. LCNEC was thought to exhibit similar aggressive behavior and early metastasis compared with SCNEC [4]. Among the 17 GB-LCNECs described, nine (53%) were diagnosed with direct hepatic invasion, and eight (47%) were identified with metastasis in the lymph nodes, liver, or bone. Fortunately, our case showed no signs of liver invasion or distant metastasis, which may have been attributed to early detection. Surgical resection, which has been determined to improve the prognosis of patients with NEC [21], is considered to be the main treatment for gallbladder NECs. The prognosis is very poor for patients with unresectable masses [22], although multimodal treatments, including chemotherapy and radiation therapy, have achieved good responses in some reports [7]. Follow-up results were reported for 13 of the 17. Among them, seven (54%) died of the disease in a median time of 14 months, while the other six patients exhibited disease-free survival (DFS) after 12 to 36 months of follow-up. Four surviving patients had some similar characteristics, such as small tumor size and no liver invasion or metastasis, and they had undergone radical surgery. The other two successful treatments for patients with liver invasion or lymph node metastasis mainly rely on extended surgery with hepatectomy and lymph node dissection. The presence of the adenocarcinoma phenotype is thought to indicate poor prognosis [2]. However, we could not make a similar conclusion according to this series of the 17 GB-LCNECs.

Conclusions

LCNEC of the gall bladder is extremely rare and is usually present along with other carcinoma types, such as adenocarcinoma, as determined histologically. The patient prognosis is poor overall, but early detection with complete resection may result in a relatively good prognosis.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
  20 in total

1.  Large cell neuroendocrine carcinoma of the gallbladder: report of two cases.

Authors:  M Papotti; P Cassoni; A Sapino; G Passarino; J E Krueger; J Albores-Saavedra
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

2.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

3.  Small-cell carcinoma of the gallbladder: report of a case and literature review.

Authors:  Amit Mahipal; Shilpa Gupta
Journal:  Gastrointest Cancer Res       Date:  2011-07

4.  Combined large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder.

Authors:  Nabeel Al-Brahim; Raeda Albannai
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

5.  A case of mixed adenoneuroendocrine carcinoma of the gallbladder arising from an intracystic papillary neoplasm associated with pancreaticobiliary maljunction.

Authors:  Yoshiyuki Meguro; Noriyoshi Fukushima; Masaru Koizumi; Naoya Kasahara; Masanobu Hydo; Kazue Morishima; Naohiro Sata; Alan T Lefor; Yoshikazu Yasuda
Journal:  Pathol Int       Date:  2014-08-22       Impact factor: 2.534

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Imprint cytological feature of large cell neuroendocrine carcinoma of the gallbladder: a case report.

Authors:  Takenobu Nakagawa; Naomi Sakashita; Koji Ohnishi; Yoshihiro Komohara; Motohiro Takeya
Journal:  J Med Invest       Date:  2013

Review 8.  Combined large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder.

Authors:  Katsuaki Sato; Tetsuya Imai; Yukihiro Shirota; Yoshimichi Ueda; Shogo Katsuda
Journal:  Pathol Res Pract       Date:  2009-11-27       Impact factor: 3.250

9.  Large cell neuroendocrine carcinoma of the gallbladder: long survival achieved by multimodal treatment.

Authors:  Chigusa Shimono; Kazuhiro Suwa; Morio Sato; Shintaro Shirai; Katsuyuki Yamada; Yasushi Nakamura; Masatoshi Makuuchi
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

10.  Mucin-producing gallbladder adenocarcinoma with focal small cell and large cell neuroendocrine differentiation associated with pancreaticobiliary maljunction.

Authors:  Hisashi Oshiro; Kenichi Matsuo; Hironori Mawatari; Yoshiaki Inayama; Shoji Yamanaka; Kiyotaka Nagahama; Itaru Endo; Hiroshi Shimada; Atsushi Nakajima; Kensuke Kubota
Journal:  Pathol Int       Date:  2008-12       Impact factor: 2.534

View more
  8 in total

1.  Large cell neuroendocrine carcinoma and adenocarcinoma of gallbladder with concomitant hepatitis C infection.

Authors:  Sarthak Soin; Bibek Singh Pannu; Phyo Thazin Myint; Amandeep Singh Dhillon
Journal:  BMJ Case Rep       Date:  2018-06-28

2.  Gallbladder Mixed Neuroendocrine-Non-neuroendocrine Neoplasm (MiNEN) Arising in Intracholecystic Papillary Neoplasm: Clinicopathologic and Molecular Analysis of a Case and Review of the Literature.

Authors:  Amedeo Sciarra; Edoardo Missiaglia; Mounir Trimech; Emmanuel Melloul; Jean-Philippe Brouland; Christine Sempoux; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

Review 3.  Mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder: case report and literature review.

Authors:  Xu Ren; Hong Jiang; Kan Sun; Xufu Qin; Yongping Qu; Tian Xia; Yan Chen
Journal:  Diagn Pathol       Date:  2022-06-17       Impact factor: 3.196

4.  A Rare Case of Pure Primary Large Cell Neuroendocrine Carcinoma of the Gallbladder.

Authors:  Rodney E Shackelford; Ekin Ozluk; Jehan Abdulsattar; Terry C Lairmore; Quyen Chu; Eric X Wei
Journal:  Case Rep Oncol Med       Date:  2022-05-21

5.  Rare case of a gallbladder neuroendocrine carcinoma.

Authors:  Masakuni Fujii; Hiroaki Saito; Junji Shiode
Journal:  Clin J Gastroenterol       Date:  2018-07-12

6.  Coexisting cancers: a mixture of neuroendocrine carcinoma and adenocarcinoma in the gallbladder: A case report.

Authors:  Hai-Jie Hu; Rong-Xing Zhou; Yong-Qiong Tan; Qiu-Yang Jing; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Shu-Jin Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Neuroendocrine Neoplasms of the Gallbladder: A Clinicopathological Analysis of 13 Patients and a Review of the Literature.

Authors:  Pengyan Wang; Jingci Chen; Ying Jiang; Congwei Jia; Junyi Pang; Shan Wang; Xiaoyan Chang
Journal:  Gastroenterol Res Pract       Date:  2021-05-22       Impact factor: 2.260

8.  Combined Adenosquamous and Large Cell Neuroendocrine Carcinoma of the Gallbladder.

Authors:  Jiyoon Jung; Yang-Seok Chae; Chul Hwan Kim; Youngseok Lee; Jeong Hyeon Lee; Dong-Sik Kim; Young-Dong Yu; Joo Young Kim
Journal:  J Pathol Transl Med       Date:  2017-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.